ThermoGenesis Holdings, Inc. · OTC:THMO
ThermoGenesis — Cesca Therapeutics — BIO CEO & Investor Conference 2019
21 slides from ThermoGenesis's conference presentation, Feb 13, 2019

Slide 1: Cesca Therapeutics Corporate Presentation
Exhibit 99.1 NASDAQ: KOOL Cesca Therapeutics Corporate Presentation Chris Xu, Ph.D, Chairman, President and CEO BIO CEO & Investor Conference (New York), February 11, 2019 1 | NASDAQ: KOOL

Slide 2: Disclosure and Forward Looking Statement
2] Disclosure and Forward Looking Statement This presentation includes statements of future expectations and other forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current

Slide 3: About Cesca Therapeutics Inc.
Fy About Cesca Therapeutics Inc. — Addressing critical unmet biomanufacturing needs for cell based therapies (CBT) Key Business Update for Year 201 Launching of three proprietary platforms for automated cellular processing: * CARTXpress™ for large scale cellular manufacturing, including CAR-T * POCX

Slide 4: Corporate Restructuring
ry Corporate Restructuring — Creates Separate Device and Clinical Divisions Figure 1. ThermoGenesis Corp (Est. July 2017) Figure 2. ThermoGenesis Reorganization (2019.1.1) Cesca Therapeutics Cesca Therapeutics Sei ioe Bay City Capital, LLC hee Bay City Capital, LLC 100% i) , Giricl) ThermoGenesis? C

Slide 5: We are Entering the Next Wave of Cell-Based Therapies
We are Entering the Next Wave of Cell-Based Therapies — The approval of two anti-CD19 CAR-T therapeutics has led to a global “Gold Rush” in CAR-T therapies M&A Deals since 2017 (Partial List) Deal Emily's Story: A Young Girl Beats Cancer with Immunotherapy ‘cancer Regression in Patents Aer Transfer

Slide 6: Current Challenge Facing Cell-Based Therapies is Manufacturing
6 Current Challenge Facing Cell-Based ifistapie> is Manufacturing — Traditional process involves the use of ficoll and at is that are labor-intensive and time consuming. i.e. it will take 8 hrs to complete just the first three slaps to process one patient sample. Ficoll-based Catetine) Final Product

Slide 7: ThermoGenesis' CAR-TXpress Manufacturing Platform
a ThermoGenesis’ CAR-TXpress™ Manufacturing Platform —-Newly launched CAR-Txpress, is a modular designed, semi-automated, closed system for large scale cellular manufacturing. E S p= Gene insertion Adaitional pos a = D D 2 a pad os a <x LAB X-BACS® oO Superiorisolation | | Superior Selection of ‘of

Slide 8: Buoyancy Activated Cell Sorting (X-BACS) Technology
FF Buoyancy Activated Cell Sorting (X-BACS™) Technology — Proprietary, new approach for separating cells from blood product using bubble technology Targetcells w/beads Non-Targetcells w/o beads CAR-TXpress™ Platform Magnetic Activated Cell Sorting (MACS) 8 | NASDAQ: KOOL Miltenyi Biotec 6 What It Is

Slide 9: X-BACS technology vs. Current Ficoll + MACS Method
X-BACS™ technology vs. Current Ficollt MACS Method — Reduces processing time to just 1-2 hours vs. 6-8 hours; increases efficiency 4x Traditional Me Step Two: MACS based CD3*T Cell purification (Shr) G S Step One: Ficoll based cat ~~ MNC Isolation (3hr) Whole Blood CAR-TXpress™ Platform One Step to

Slide 10: CAR-TXpress Platform Significantly Reduces Processing Time
10 CAR-TXpress™ Platform Significantly Reduces Processing Time While Improving Cell Recovery Cesca’s technology reduces cell selection time from eight hours to two hours ur technology improves cel recoverise after isolation and selection by up to-45% WE Saveson cGMP ML Savesconstafftime Ml increases

Slide 11: BioArchive: Fully Automated Storage of Clinical Product
BioArchive®: Fully Automated Storage of Clinical Product — Fully robotic storage and retrieval system for cryopreserving cell-based therapeutics, has already been used in four BLA applications BioArchive® System ‘Sample is being stoved Once the sample reaches ‘onrack "SO'C tis oboteally Individual s

Slide 12: BioArchive: More Viable Stem & Effector Cells
BioArchive® More Viable Stem & Effector Cells Provides Faster Engraftment and Higher Survival Rates Platelet Engraftment Overall Survival by Processing Method and Freezer % with Platelet = 50,000 THe OTT ‘8 760 Ea % 160, 20 Ea Days Post-Transplant Days Post-Transplant Days Post-Transplant BioArchive

Slide 13: BioArchive: Market Penetration
2B BioArchive®: Market Penetration — 303 BioArchive Systems, 129 sites in 37 countries BioArchive® System 43 | NASDAQ: KOOL The America’s 111 Systems 41 Cord Blood Banks 5 Countries Europe/Russia/Africa 79 Systems 42 Cord Blood Banks 19 Countries ‘Asia/Mid East 113 Systems 46 Cord Blood Banks 13 Cou

Slide 14: AXP: Leading Automated Technology for Stem Cell Banking
AXP®: Leading Automated Technology for Stem Cell Banking —A fully automated system for isolation of stem cells from cord blood with superior performance, a leading automated cellular processing system for stem cell banking worldwide Notable public and Recovery rate comparison between AXP” vs. compet

Slide 15: PXP: Leading Automated Technology for Point-of-Care
PXP®: Leading Automated Technology for Point-of-Care -A fully automated system for isolation of stem cells from bone marrow or peripheral blood for various sources within 45 mins, allowing direct autologous point-of-care (PoC) applications POcXpress Platform 45 | NASDAQ: KOOL PXP™ System EFFICIENT A

Slide 16: Clinic application scenarios with point-of-care systems
16] | Clinic application scenarios with point-of-care systems Indication Pre-Clinical/Pilot Pi/Ib Pu Pll Platform Market Est. Vascular E AMI Single Patient POCXpress $700M = cu POCXpress $2B Pe Non-Healing Ulcer $800M 3 Orthopedic a Spinal Fusion POCXpress $800M i) Osteoarthritis POCXpress $5B Non-U

Slide 17: A Full Product Line for Automated Cellular Processing
— From stem cell banking, to point-of-care clinical applications, to large scale manufacturing 7 A Full Product Line for Automated Cellular Processing 41.AutoXpress® Platform - Stem Cell Banking 2.POCXpress Platform - Point-of-Care Application 3.CARTXpress™ Platform - Large Scale Cell Mfg. AXP/AXP I

Slide 18: ThermoGenesis Business Strategy
ThermoGenesis Business Strategy — Transforming from a medical device company to a leading solution provider. Past 18 months Growth Strategy + Kite received ‘second CD19 CART approvaltromrDa | [+ 7G launched POC- + TG receivedsecond| | Xpress platform for |CAR-TXpress patent point-of-care (PoC) romUS

Slide 19: Vital statistics
FY | vital statistics Major inflection po 9 419 | NASDAQ: KOOL NASDAQ Share Price Share Price 52 Week Range Shares Outstanding Market Capitalization Revenue (2018) * Cash ~ * As of February 8, 2019 * As of September 30, 2018 KOOL $0.35 * $0.21 - $3.92 21.6M $7.6M $10M $2.2M ThermoGenesis® CESCA

Slide 20: Experienced Leadership Team
20} Experienced Leadership Team Chris Xu, PhD/MBA, Chairman, President and Chief Executive Officer 20+ years in life sciences and pharmaceutical industry Founder of the Boyalife Group; fostered more than 20+ private public companies Haihong Zhu, President of ThermoGenesis Corp 25+ years involved in

Slide 21: Company Contact / Investor Contact
Company Contact: Investor Contact: For more information: Cesca Therapeutics Inc. Rx Communications Cesca Therapeutics Inc, visit: Wendy Samford Paula Schwartz n 916-858-5191 917-322-2216 ThermoGenesis Corp, visit: [email protected] [email protected] v.thermogenesi r4 gCES 21 | NASDAQ: KOOL T
Source: SEC EDGAR · 8-K filed Feb 13, 2019
More decks from ThermoGenesis Holdings, Inc.
H. C. Wainwright BioConnect Conference 202224 slides · Jan 10, 2022
H.C. Wainwright 23rd Annual Global Investment Conference 202119 slides · Sep 15, 2021
Corporate Update (May 2020)18 slides · May 14, 2020
Q3 2019 Earnings Presentation26 slides · Nov 20, 2019
Cesca Therapeutics — BIO Investor Forum, San Francisco 201925 slides · Oct 22, 2019
Cesca Therapeutics — HC Wainwright 21st Annual Global Investment Conference (September 2019)20 slides · Sep 11, 2019